2021
DOI: 10.1097/hs9.0000000000000573
|View full text |Cite
|
Sign up to set email alerts
|

Hijacking the Pathway: Perspectives in the Treatment of Mature T-cell Leukemias

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
4
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
4

Relationship

1
3

Authors

Journals

citations
Cited by 4 publications
(7 citation statements)
references
References 36 publications
(91 reference statements)
0
4
0
Order By: Relevance
“…Whether MTX or CP should be given as first line therapy is not clear. To clarify this situation, a phase II randomized trial comparing first-line MTX versus CP ( NCT01976182 ) is ongoing ( 26 ).…”
Section: Case Reportsmentioning
confidence: 99%
See 2 more Smart Citations
“…Whether MTX or CP should be given as first line therapy is not clear. To clarify this situation, a phase II randomized trial comparing first-line MTX versus CP ( NCT01976182 ) is ongoing ( 26 ).…”
Section: Case Reportsmentioning
confidence: 99%
“…Considering the pathogenesis of LGL leukemia, various specific inhibitors were evaluated in T-LGLL. Tofacitinib, a JAK3-specific inhibitor, showed in T-LGLL patients an improvement of RA symptoms and a hematological response in 6/9 (67%) cases ( 26 , 41 ). BNZ-1 a multi-cytokine inhibitor that inhibits interleukin (IL)-2, IL-15 and IL-9 signaling showed promising results in reducing cytokine mediated cell survival being investigated in a phase I/II trial ( 42 ).…”
Section: Case Reportsmentioning
confidence: 99%
See 1 more Smart Citation
“…It is assumed that prolonged stimulation in this context may cause LGL clonal expansion, associated with the deregulation of several pro- and anti-apoptotic signaling pathways. Recent studies point to the constitutional activation of STAT3, and more rarely of STAT 5b, as a key concept in the etiopathogenesis of LGL [ 6 , 10 , 11 ].…”
Section: Introductionmentioning
confidence: 99%
“…Treatment-defining prospective trials are hardly available. For a summary of tested strategies see ( 15 ). Furthermore, there is a great deal of uncertainty regarding the optimal timing of treatment initiation.…”
Section: Introductionmentioning
confidence: 99%